Abstract:Abstract BACKGROUND Post-gadolinium MRI is considered the mainstay of radiological monitoring of treatment effects in patients with a glioblastoma. However, the radiotherapy(RT)-induced abnormality, pseudoprogression, is difficult to distinguish from real tumor growth. Perfusion MRI (pMRI), including Arterial Spin Labeling (ASL) and Dynamic Susceptibility Contrast (DSC), may help in this differentiation. Evaluation of RT effects is usually discussed during multidisciplinary team meetings (MDTM), after which a decision regarding (dis)continuation of anti-tumor treatment is made. It is currently unknown whether pMRI impacts such treatment decisions. This study evaluated how accurate pMRI and the MDTM are in distinguishing tumor progression from pseudoprogression in glioblastoma. MATERIAL AND METHODS Population and outcome: Glioblastoma patients who received postoperative RT were retrospectively included from 2015 to 2020. ASL, DSC, FLAIR and post-gadolinium 3D-T1 at 3 months post-RT were visually scored for probability of radiological tumor progression. These radiological scores, as well as the outcome of MDTM, were compared to the final outcome (i.e. tumor progression or pseudoprogression) set at 9 months after RT initiation. Statistical analysis: Diagnostic accuracy of pMRI, conventional MRI and MDTM was assessed by 2x2 tables, sensitivity and specificity (including AUC values). In case the MDTM was inconclusive, subsequent analysis was used to determine whether pMRI has additional value. A multivariable logistic regression model was constructed to assess which clinical parameters (age, surgery type, IDH mutation status, MGMT methylation status, KPS score, chemotherapy and pMRI evaluation) were associated with the outcome of the MDTM assessment. RESULTS Sixty-five patients with a glioblastoma met the inclusion criteria (40 male, mean age 60+/-13 years, median KPS of 90). For all METHODS , the sensitivity for detecting true disease progression was poor to moderate (32-62%). Although sensitivity was higher when adding pMRI to conventional imaging (56% versus 32%), specificity was lower (80% versus 93%). AUC values were comparable (range 0.63-0.74), but highest for MDTM evaluation (0.74). For the 26% of patients where MDTM was inconclusive, pMRI shows increased sensitivity compared to conventional MRI in detecting tumor progression (respectively 36% versus 0%). The multivariable regression analysis showed significant associations for KPS score (OR = 0.84 (95% CI: 0.77-0.91)) and radiological assessment based on pMRI with MDTM outcome (OR = 0.09 (95% CI: 0.02-0.52)). CONCLUSION This study shows that perfusion MRI has added value for detection of tumor progression within the MDTM assessment in clinical decision-making for glioblastomas, especially when the MDTM outcome is uncertain. For this decision, the role of perfusion MRI and the KPS score are most important.

Suivi Longitudinal IRM Et SRM Proton De Patients Attients De Tumeur Gliale Traitee Par Temodal

Suivi Longitudinal IRM Et SRM 1H De 15 Patients Atteints De Tumeur Oligodendrogliale Ou De Gliomatose Sous Temodal

Importance Des Variations Spectrales Durant 36 Mois De Suivi Longitudinal IRM Et SRM De 80 Patients Atteints De Glioblastomes Traités

Intérêt Des Séquences Avancées En IRM Dans L’évaluation À La Réponse Au Bevacizumab. Suivi Multimodal De 20 Glioblastomes

Five-Year Longitudinal MRI Follow-up and (1)H Single Voxel MRS in 14 Patients with Gliomatosis Treated with Temodal, Radiotherapy and Antiangiogenic Therapy.

Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging

Évaluation longitudinale de patients CMT1A sur 1 an : apport de l’IRM neuromusculaire quantifiée

Étude prospective des biomarqueurs de marche et d’IRM multimodale chez les patients de la cohorte GAIT’N’PARK présentant une atrophie multisystématisée

Nimg-56. Magnetic Resonance Spectroscopy In The Post-Treatment Metabolic Characterization Of Brain Tumors Of Glial Origin Of Central Nervous System

Identification de biomarqueurs longitudinaux dans les ataxies spinocérébelleuses

Multidomain and long-term cognitive evaluation in malignant glioma patients.

Combined imaging biomarkers for therapy evaluation in glioblastoma multiforme: correlating sodium MRI and F-18 FLT PET on a voxel-wise basis

Early Metabolic Changes in 1H-MRSI Predictive for Survival in Patients With Newly Diagnosed High-grade Glioma

The Utility of Spectroscopic MRI in Stereotactic Biopsy and Radiotherapy Guidance in Newly Diagnosed Glioblastoma

Faisabilité et intérêt de la dosimétrie dans le cadre de la thérapie au Lu177-DOTATATE chez des patients avec des méningiomes réfractaires

Irm À 7 Tesla Et Sclérose En Plaques: Innovations Et Nouvelles Perspectives

Correlation between rCBV Delineation Similarity and Overall Survival in a Prospective Cohort of High-Grade Gliomas Patients: The Hidden Value of Multimodal MRI?

Recréer in vivo à partir de l’IRM clinique des cartographies spécifiques du contenu myélinique dérivées de la TEP grâce à l’Intelligence artificielle générative chez les patients atteints de SEP

Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma

P11.07.A PERFUSION-MRI BASED DIFFERENTIATION BETWEEN EARLY TUMOR PROGRESSION AND PSEUDOPROGRESSION IN GLIOBLASTOMA AND ITS USE IN CLINICAL PRACTICE

Tailoring glioblastoma treatment based on longitudinal analysis of post-surgical tumor microenvironment